Shigeki Tanishima
Overview
Explore the profile of Shigeki Tanishima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
So E, Hayashi H, Shimozaki K, Horie S, Kishimoto S, Chida A, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39961905
Background: Precision medicine is a promising therapeutic strategy for pancreatic cancer. However, only a few patients are eligible for genotype-matched treatments because of the low detection rate of actionable genomic...
2.
Nakamura K, Ishikawa M, Kawano R, Aimono E, Mizuno T, Nohara S, et al.
Cancer Med
. 2024 Jul;
13(14):e70052.
PMID: 39054873
Background: PIK3CA mutations are implicated in various cancers, but the implications of multiple concurrent mutations and their orientations within the gene have not been fully explored. Methods: In this study,...
3.
Ishikawa M, Nakamura K, Kawano R, Hayashi H, Ikeda T, Saito M, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672586
The usefulness of comprehensive genomic profiling (CGP) in the Japanese healthcare insurance system remains underexplored. Therefore, this large-scale study aimed to determine the usefulness of CGP in diagnosing digestive cancers....
4.
Hayashi H, Kunimasa K, Tanishima S, Nakamura K, Ishikawa M, Kato Y, et al.
Cancer Sci
. 2023 Dec;
115(2):682-686.
PMID: 38086530
Germline BRCA1/2 variants in comprehensive genomic profiling (CGP) often exhibit variant allele frequency (VAF) exceeding 50%. However, when genomic loss occurs at the ipsilateral allele, including the germline variant in...
5.
Nakamura K, Hayashi H, Kawano R, Ishikawa M, Aimono E, Mizuno T, et al.
Cancer Sci
. 2023 Dec;
115(2):635-647.
PMID: 38041241
Tumor sensitivity to platinum (Pt)-based chemotherapy and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors is increased by homologous recombination deficiency-causing mutations; in particular, reversion mutations cause drug resistance by restoring protein...
6.
Takamatsu R, Nakamura K, Suzuki O, Okada C, Mori R, Kawano R, et al.
Cancer Sci
. 2023 Apr;
114(7):2848-2859.
PMID: 37119014
The microsatellite instability (MSI)/mismatch repair (MMR) status is one of the critical genomic biomarkers for predicting patient response to immune checkpoint inhibitors (ICIs). In this study, we aimed to investigate...
7.
Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, et al.
Cancer Med
. 2023 Jan;
12(7):8154-8165.
PMID: 36645189
Background: The significance of BRCA alterations has been implicated in the development of metastatic castration-resistant prostate cancer (PC). The details of the frequency and significance of BRCA alterations in localized...
8.
Ogiri M, Seishima R, Nakamura K, Aimono E, Matsui S, Shigeta K, et al.
Future Oncol
. 2022 Jul;
PMID: 35818975
To evaluate the significance of next-generation sequencing-based gene panel testing in surgically resectable colorectal cancer by analyzing real-world data. A total of 107 colorectal cancer patients who underwent curative surgery...
9.
Yamada T, Nakanishi Y, Hayashi H, Tanishima S, Mori R, Fujii K, et al.
HPB (Oxford)
. 2021 Dec;
24(7):1035-1043.
PMID: 34903468
Background: Lymph node metastasis (LNM) is one of the most adverse prognostic factors in extrahepatic cholangiocarcinoma (EHCC) cases. As next-generation sequencing technology has become more widely available, the genomic profile...
10.
Shimozaki K, Hayashi H, Tanishima S, Horie S, Chida A, Tsugaru K, et al.
Sci Rep
. 2021 Oct;
11(1):20003.
PMID: 34625576
Various malignancies exhibit high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). The MSI-IVD kit, a polymerase chain reaction (PCR)-based method, was the first tumor-agnostic companion diagnostic to detect MSI...